Other News

Stereotaxis to Ring the Opening Bell® of the New York Stock Exchange

ST. LOUIS, Jan. 16, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that David Fischel, Chairman and CEO, will ring the Opening Bell® of the New York Stock Exchange on Tuesday, January 21, 2020 to celebrate Stereotaxis’ positive impact […]

Leading Cardiovascular Researcher And PAD Treatment Pioneer, Dr. Christopher Kevil, To Chair JanOne Scientific Advisory Board

Kevil brings global scientific expertise to advance JanOne’s drug development portfolio and advise on upcoming Phase 2b clinical trials for PAD LAS VEGAS, Jan. 16, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ:JAN) appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board. In this role, Dr. Kevil will […]

FDA Grants Fast Track Designation to Arena Pharmaceuticals’ APD418 for Development in Decompensated Heart Failure Patients

– APD418 currently in Phase 1 clinical investigation – data expected this year SAN DIEGO, Jan. 16, 2020 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for APD418, a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for the treatment of […]

Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer™

VANCOUVER, Jan. 15, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced receipt of an Administrative Acceptance […]

Emboline Completes Enrollment in SafePass 2 Clinical Study of Emboliner Embolic Protection Catheter

Early Results from First 24 Patients Show Excellent Safety Profile and Technical Performance, with Significant Debris Capture and Removal in All Patients SANTA CRUZ, Calif.–(BUSINESS WIRE)–Emboline™, Inc., developer of total embolic protection technology for transcatheter aortic valve replacement (TAVR), today announced completion of enrollment in its SafePass™ 2 clinical study […]

AngioSoma Acquires Technology Related to 15 Patents

Houston, Jan. 15, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that we have acquired the unconditional ownership of the following intellectual property and the exclusive right to develop, formulate and market: ·         Method and Composition for Reducing Dysfunction in Angioplasty […]

Cardax, Inc. Announces Reverse Stock Split of Common Stock

HONOLULU, Jan. 14, 2020 /PRNewswire/ — Cardax, Inc. (OTCQB:CDXI) today announced it will effect a 200-for-1 reverse stock split of its issued and outstanding common stock. Pursuant to the Certificate of Amendment to the Company’s Certificate of Incorporation filed with the Secretary of State of Delaware, the reverse stock split will be effective at 12:01 […]

Zebra Medical Vision Expands Its Footprint in North America and Appoints a New CEO

KIBBUTZ SHEFAYIM, Israel–(BUSINESS WIRE)–Zebra Medical Vision, the deep-learning medical imaging analytics company, announces today that Ohad Arazi has been appointed as Chief Executive Officer, succeeding Co-Founder Eyal Gura, who will continue as Chairman of the board. Mr Arazi brings to Zebra-Med extensive leadership experience in healthcare IT and medical imaging, […]

Matinas BioPharma Announces Closing of Public Offering of Common Stock

BEDMINSTER, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) — (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the closing  of its underwritten registered public offering of 32,260,000 shares of its common stock, offered at a price to the public of […]

PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

PhaseBio to be responsible for all development, manufacturing and commercialization MALVERN, Pa. and SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has signed an agreement […]